Catalog No.
Product Name
Application
Product Information
Citations
-
IRAK4 Inhibitor
Emavusertib hydrochloride is an orally active inhibitor targeting IRAK4, with an IC50 of 57 nM, and FLT3. This compound effectively inhibits NF-κB and MyD88 signaling pathways, resulting in decreased production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, as it promotes apoptosis in cancer cells and demonstrates antitumor efficacy in mouse model studies. -
HDAC1/2 and CDK2 Inhibitor
HDAC1/2 and CDK2-IN-1 is a dual inhibitor targeting HDAC1, HDAC2, and CDK2, with IC50 values of 70.7 μM, 23.1 μM, and 0.80 μM, respectively. This compound effectively disrupts the cell cycle and promotes apoptosis in tumor cells, demonstrating significant in vivo antitumor activity. It is suitable for research applications focused on cancer biology and therapeutic interventions targeting histone deacetylases and cyclin-dependent kinases. -
HDAC/MBLAC2 Inhibitor
Pracinostat dihydrochloride is a potent inhibitor of histone deacetylases (HDACs), demonstrating IC50 values in the range of 40-140 nM, making it a valuable tool in cancer research. In addition, it effectively inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) with an EC50 below 10 nM, highlighting its potential use in studies related to epigenetic regulation and resistance mechanisms in cancer therapies. -
Immunomodulator
Laquinimod sodium is a potent immunomodulator targeting neuroinflammation and neurodegeneration within the central nervous system. This orally available carboxamide derivative effectively reduces astrocytic NF-κB activation, offering protection against Cuprizone-induced demyelination. Laquinimod sodium is applicable in research focused on relapsing-remitting and chronic progressive forms of multiple sclerosis, as well as in studies of various neurodegenerative diseases. -
Cereblon Modulator
Avadomide hydrochloride is an oral cereblon modulator that targets cereblon E3 ligase activity. By inhibiting the NF-κB signaling pathway and arresting the cell cycle at the G1 phase, it effectively induces apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. This compound demonstrates significant antitumor and immunomodulatory properties, making it a valuable reagent for cancer research applications. -
Apoptosis Inducer
Apoptosis Inducer 46 targets apoptotic pathways to induce cell death selectively in metastatic triple-negative breast cancer (TNBC) cells. It demonstrates potent growth inhibitory effects, specifically causing G2/M phase cell cycle arrest and promoting apoptotic cell death in MDA-MB-231 cells. Additionally, Apoptosis Inducer 46 inhibits NF-κB nuclear translocation, highlighting its potential for research applications in the study of TNBC. -
HDAC Inhibitor
HDAC-IN-73 is a potent histone deacetylase (HDAC) inhibitor targeting HDAC1 and HDAC6, with IC50 values of 0.17 µM and 0.49 µM, respectively. Its enhanced activity against HDAC6 demonstrates a nine-fold greater potency compared to PsA, making it a valuable compound in the field of cancer research. HDAC-IN-73 exhibits significant antiproliferative effects, induces apoptosis, and triggers G2/M cell cycle arrest, positioning it as a promising candidate for investigating therapies in colon cancer and other malignancies. -
HDAC Inhibitor
HDAC-IN-96 is a selective inhibitor of histone deacetylases 1 and 2 (HDAC1/2), exhibiting IC50 values of 457.1 nM and 433.7 nM, respectively. This compound demonstrates significant cytotoxicity against various hematological tumor cell lines, including RS4;11, K562, RPMI-8226, and U266, with IC50 values between 2.11 and 5.35 μM. HDAC-IN-96 has been shown to induce apoptosis and cause S phase arrest in cancer cells, making it a valuable tool for research in hematological malignancies such as acute lymphoblastic leukemia. -
Aurora A/Aurora B/HDAC1/HDAC2 Inhibitor
Aurora kinase/HDAC-IN-1 is a potent dual inhibitor targeting Aurora A, Aurora B, HDAC1, and HDAC2. This compound promotes histone H3 acetylation, inhibits Aurora A phosphorylation and downstream signaling, and induces apoptosis through G2/M cell-cycle arrest. It demonstrates significant antiproliferative activity in colorectal cancer cells, with an IC50 of 30.2 nM in HCT-116 cells, and effectively suppresses tumor growth in HCT-116 colorectal cancer xenograft mouse models. This reagent is valuable for research in cancer biology and therapeutic application development. -
HDAC1/CDK7 Inhibitor
HDAC1/CDK7-IN-1 is a dual inhibitor targeting HDAC1 and CDK7, exhibiting IC50 values of 893 nM and 248 nM, respectively. This compound effectively inhibits the proliferation of cancer cell lines, including MDA-MB-231, MCF-7, A549, and HCT-116. Additionally, HDAC1/CDK7-IN-1 induces cell cycle arrest and apoptosis specifically in HCT-116 cells, while also disrupting their migratory capacity. These properties make it a valuable tool for cancer research, particularly in exploring therapeutic strategies that target epigenetic regulation and cell cycle dynamics. -
HDAC Inhibitor
WMJ-J-09 is a potent HDAC inhibitor with sub-nanomolar activity, exhibiting IC50 values of 7.5 nM against HDAC1 and 3.9 nM against HDAC6, along with notable activity towards HDAC2, HDAC3, and HDAC8. This compound effectively disrupts the cell cycle and promotes apoptosis in cancer cells through the LKB1-AMPK-p38MAPK-p63-survivin signaling pathway. By inhibiting HDAC enzyme activity, WMJ-J-09 leads to the acetylation of critical proteins, thus contributing to the regulation of cell death in cancer models, such as HCT116 and FaDu cells. -
HDAC Inhibitor
TH-6 is a potent inhibitor of histone deacetylases (HDACs), demonstrating IC50 values of 0.115 µM for HDAC1, 0.135 µM for HDAC2, 0.242 µM for HDAC3, 0.138 µM for HDAC6, and 2.120 µM for HDAC8. This compound effectively inhibits cell migration and invasion while promoting apoptosis and inducing cell cycle arrest in the G2/M phase. TH-6 exhibits significant anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. -
HDAC Inhibitor
HDAC-IN-36 is a potent HDAC (histone deacetylase) inhibitor that targets HDAC6 with an IC50 of 11.68 nM. This compound demonstrates significant biological activity by promoting apoptosis, enhancing autophagy, and inhibiting cellular migration. HDAC-IN-36 is applicable in cancer research, particularly in studies focusing on anti-tumor and anti-metastatic mechanisms in breast cancer. -
HDAC Inhibitor
Trichostatin C is an HDAC inhibitor that plays a crucial role in modulating gene expression by preventing the deacetylation of histones. This compound exhibits significant anticancer activity, inducing apoptosis and causing cell cycle arrest in the G2/M phase, making it particularly effective against lung cancer and urothelial bladder cancer. Additionally, Trichostatin C promotes differentiation in Friend leukemic cells and demonstrates antifungal properties, highlighting its potential in various research applications related to cancer biology and fungal infections. -
IKK/STAT3 Dual Inhibitor
ACHP is a selective IκB kinase (IKK) and STAT3 dual inhibitor, demonstrating potent inhibitory activity with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. It effectively disrupts the STAT3 signaling pathway, leading to cancer cell cycle arrest and apoptosis. Additionally, ACHP exhibits significant anti-inflammatory properties in preclinical models, such as the mouse ear edema model. This compound is a valuable tool for research in anti-inflammatory and anti-cancer studies, including applications in multiple myeloma and leukemia. -
JMJD3/HDAC1/HDAC6 Inhibitor
JMJD3/HDAC-IN-1 is a dual inhibitor targeting both Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylases HDAC1 and HDAC6. With an IC50 value of 16 nM for HDAC1, this compound induces hypermethylation of histone H3K27 and hyperacetylation of H3K9, promoting apoptosis through cleavage of caspase-7 and PARP. JMJD3/HDAC-IN-1 demonstrates significant anti-cancer activity by inhibiting cell cloning, migration, and invasion, making it valuable in cancer research and therapeutic studies. -
Antioxidant
Astaxanthin is a potent antioxidant primarily targeting NF-κB, leading to the down-regulation of VEGF in blood glucose regulation. This carotenoid exhibits significant anti-cancer properties by inhibiting cell proliferation, enhancing apoptosis, and preventing migration and invasion through PPARγ activation and STAT3 expression reduction. Additionally, astaxanthin demonstrates neuroprotective and anti-inflammatory activities, making it applicable in various research fields, including cancer, diabetic retinopathy, and cardiovascular disease, as well as in the enhancement of animal feed coloration. -
Short-chain Fatty Acid
Sodium propionate is a short-chain fatty acid with multiple biological activities, primarily functioning as an oral bioactive compound. It enhances PPAR-γ activity while inhibiting NF-κB activation, leading to reduced COX-2 expression and nitric oxide production. Additionally, sodium propionate has demonstrated the ability to induce apoptosis and autophagy, exhibit anticancer effects against glioblastoma, and provide neuroprotective, antioxidant, and anti-inflammatory properties. This compound is suitable for research applications in areas such as spinal cord injury and Alzheimer's disease. -
TLR7/8 Antagonist
Afimetoran is a selective and highly bioavailable antagonist of Toll-like receptors 7 and 8 (TLR7/8). It effectively inhibits TLR7/8-mediated activation of the NF-κB signaling pathway and can reverse TLR7-induced resistance to steroid-driven apoptosis in plasmacytoid dendritic cells. This compound is particularly relevant for research into inflammation and autoimmune diseases, including systemic lupus erythematosus. -
HDAC3/p-STAT3 Inhibitor
1-Stearoyl-sn-glycero-3-phosphocholine is an inhibitor of histone deacetylase 3 (HDAC3) and the phosphorylation of signal transducer and activator of transcription 3 (p-STAT3). This compound has demonstrated the ability to induce apoptosis and exhibits significant anticancer activity in chronic myelogenous leukemia (CML) K562 cells. It serves as a valuable tool for researchers investigating the therapeutic potential of HDAC inhibitors in cancer treatment. -
Vascular Function Regulator
12-HETE is a significant metabolite of arachidonic acid produced via 12-lipoxygenase (12-LOX) catalysis, functioning as a vascular function regulator. It exhibits dose-dependent inhibition of cell apoptosis and promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway. Additionally, 12-HETE has been shown to possess both anti-thrombotic and pro-thrombotic effects, as well as neuromodulatory properties, making it valuable for research in vascular biology and related therapeutic areas. -
TRIP13 Inhibitor
DCZ0415 is a potent inhibitor of TRIP13, interfering with the nonhomologous end joining DNA repair mechanism and inhibiting NF-κB activity. This compound exhibits significant anti-myeloma activity in vitro, in vivo, and in primary cells obtained from drug-resistant myeloma patients, making it a valuable tool for research into therapeutic strategies against multiple myeloma. Its mechanism of action offers insights into the role of TRIP13 in cancer biology and the potential for targeted therapies. -
TLR2/4 Inhibitor
Robinin is a flavonoid that acts as an inhibitor of Toll-like receptors 2 and 4 (TLR2/4), modulating the TGF-β, TLR4/NF-κB, and TLR2-PI3k-AKT signaling pathways. This compound demonstrates significant anti-inflammatory and anti-tumor properties. Additionally, Robinin has been shown to enhance the anti-inflammatory effects of Methotrexate in experimental arthritis models and may mitigate cardiac toxicity induced by Doxorubicin. These attributes make Robinin a valuable reagent for research applications in inflammation and cancer therapy. -
Mucolytic Agent
Carbocisteine is an orally active mucolytic agent primarily targeting the modulation of mucous viscosity in respiratory conditions. It inhibits the phosphorylation of NF-κB p65 and ERK1/2, and further regulates the interplay between Nrf2/HO-1 and NF-κB pathways. Additionally, carbocisteine has demonstrated anti-apoptotic properties. This reagent is primarily utilized in research related to chronic obstructive pulmonary disease (COPD). -
ACE/IKK-β/PKC Inhibitor
Plantainoside D is a phenylethanoid glycoside that functions primarily as an inhibitor of IKK-β, with additional inhibitory effects on angiotensin-converting enzyme (ACE) and protein kinase C (PKC). It exhibits significant biological activities, including the reduction of glutamate release in the rat cerebral cortex, alleviating cell apoptosis through the inhibition of reactive oxygen species (ROS) and NF-κB activation. Additionally, Plantainoside D has been shown to improve outcomes in acute lung injury induced by sepsis via modulation of the Sirt3/NLRP3 signaling pathway. This compound is applicable in studies of neuroprotection, antioxidant activity, anti-inflammatory responses, and antihypertensive effects. -
TREM-1 Inhibitor
Nangibotide is a synthetic peptide that serves as a TREM-1 receptor inhibitor. By inhibiting NF-κB and NLRP3 inflammasome activation, Nangibotide effectively reduces the release of pro-inflammatory cytokines such as IL-1β and IL-8 and mitigates apoptosis. This reagent is valuable for research applications related to excessive inflammatory responses, including studies on myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure. Additionally, Nangibotide offers protective effects on tissues, such as the liver and lung, during inflammatory conditions. -
Bioactive Peptide
MOTS-c (human) is a bioactive peptide derived from mitochondria that modulates the AMPK/PGC-1α pathway, thereby enhancing insulin sensitivity. This peptide inhibits the folate cycle and de novo purine synthesis, elevating AICAR levels to activate AMPK, which regulates the Nrf2/Keap1 antioxidant pathway and suppresses the NF-κB inflammatory pathway. MOTS-c promotes mitochondrial biogenesis and energy metabolism, resulting in improvements in glucose and lipid metabolism, anti-oxidative stress, and neuroprotection. It is applicable in research studying type 2 diabetes, traumatic brain injury, inflammatory diseases, and age-related metabolic disorders. -
Prolyl-hydroxylase Inhibitor
Ethyl 3,4-dihydroxybenzoate is a competitive inhibitor of prolyl hydroxylase, effectively penetrating the blood-brain barrier. By inhibiting the hydroxylation of hypoxia-inducible factor (HIF), it stabilizes HIF-1α, thereby activating downstream pathways that promote autophagy and apoptosis in tumor cells. Additionally, it modulates inflammatory responses, inhibits the NF-κB pathway, enhances vascular permeability, and supports osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate is beneficial for research applications focused on cancer therapeutics, cardiovascular protection, bone metabolism regulation, and high-altitude cerebral edema management. -
Keap1-Nrf2 Protein-Protein Inhibitor
CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, exhibiting an IC50 of 0.63 µM. This compound demonstrates significant anti-inflammatory and antioxidant properties by activating the Nrf2-dependent pathway and inhibiting the NF-κB-related inflammatory response. CPUY192018 is ideal for research applications focused on inflammation-related diseases and the modulation of oxidative stress. -
Anticancer/Antiparasitic Agents
Bruceine A, a natural quassinoid, primarily targets NF-κB and PFKFB4, demonstrating a Kd of 44 nM. This compound exhibits potent anticancer and antiparasitic activities, effectively inhibiting cancer cell migration and inducing apoptosis while also disrupting the cell cycle. Bruceine A is a valuable research tool for studying pancreatic cancer, breast cancer, and parasitic infections. -
Anti-inflammatory agent
Hederacoside C is a potent anti-inflammatory agent that targets the MAPK/NF-κB signaling pathway. It exerts its biological activity by inhibiting the activation of this pathway, resulting in a reduction of inflammation. In addition to its anti-inflammatory properties, Hederacoside C also demonstrates antibacterial activity, making it a valuable compound for research applications focused on inflammatory diseases and infections. -
Drug Derivative
(+)–Rocaglamide is a selective inhibitor of heat shock factor 1 (HSF1), exhibiting an IC50 value of 50 nM. It is effective in inhibiting NF-κB activation in T-cells and the activity of the translation initiation factor eIF4A. Research applications include its potential use in anti-inflammatory treatments and as an anticancer agent, particularly against leukemia. This compound is derived from the genus Aglaia and demonstrates promising therapeutic properties for various conditions, including inflammatory diseases. -
HDAC1/HDAC2 Inhibitor
MRLB-223 is a selective inhibitor of HDAC1 and HDAC2, demonstrating potent activity against tumor cells. It induces histone hyperacetylation and activates the intrinsic apoptotic pathway, leading to tumor cell apoptosis and degradation of Bcr-Abl in a caspase-dependent manner. Notably, MRLB-223 mediates p53-independent cell death in Bcr-Abl-expressing myeloid cells and shows efficacy in animal models of Eμ-myc lymphoma. This compound is valuable for research focusing on the mechanisms of lymphomagenesis and therapeutic strategies for Eμ-myc lymphoma. -
GADD45β/MKK7 Inhibitor
DTP3 TFA is a highly selective inhibitor of GADD45β/MKK7, targeting a critical pathway involved in cell survival in cancer cells downstream of the NF-κB signaling cascade. This compound exert biological activity by disrupting the function of the GADD45β/MKK7 module, influencing cellular responses to DNA damage and stress. DTP3 TFA serves as a valuable tool in cancer research, particularly in studies investigating the mechanisms of cell survival and the potential for therapeutic interventions in malignancies associated with aberrant NF-κB activity. -
Anti-Inflammatory Agent
Vitisin A is a resveratrol tetramer with potent anti-inflammatory properties. It exerts its biological activity by inhibiting LPS-induced nitric oxide (NO) and inducible nitric oxide synthase (iNOS) production through the down-regulation of ERK1/2, p38, and NF-κB signaling pathways. Additionally, Vitisin A demonstrates antioxidative, anticancer, and neuroprotective effects while also inhibiting adipocyte differentiation. This compound is derived from the roots of Vitis vinifera and serves as a valuable reagent for research in inflammation and related diseases. -
Inflammation Inhibitor
Resolvin D5 is an anti-inflammatory agent primarily targeting the GPR32 receptor, effectively modulating inflammation responses. It alleviates Paclitaxel-induced mechanical allodynia and inflammatory pain in male mice through mechanisms that do not involve TRPV1 or TRPA1 channels. Resolvin D5 reduces LPS-induced ERK phosphorylation and NF-κB nuclear translocation while downregulating pro-inflammatory mediators, inhibiting Th17 differentiation, and promoting regulatory T cell differentiation. This compound is particularly relevant for research on chemotherapy-induced peripheral neuropathy, inflammatory pain, and rheumatoid arthritis. -
NF-κB&ERK1/2 Inhibitor
OP-1118 is a potent dual inhibitor of NF-κB and ERK1/2, targeting critical signaling pathways involved in inflammation and cell survival. This compound demonstrates significant anti-inflammatory, cytoprotective, anti-apoptotic, and antibacterial activities by inhibiting the phosphorylation of NF-κB and ERK1/2, leading to a reduction in pro-inflammatory cytokine expression. In preclinical models of Clostridium difficile infection, OP-1118 effectively mitigates toxin-induced intestinal inflammation, cellular damage, and apoptosis, with its protective effects possibly reversible by PMA. This makes OP-1118 a valuable reagent for research into inflammatory conditions and therapeutic interventions. -
Anti-inflammatory Agent
24-O-Acetyllycoclavanol is a triterpenoid compound that functions as an anti-inflammatory agent by selectively targeting the NF-κB and ERK1/2 signaling pathways. Its biological activity includes the inhibition of lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), leading to decreased production of inflammatory mediators like nitric oxide (NO), IL-1β, and IL-8. This compound is particularly relevant for research applications in the context of inflammatory bowel disease (IBD) and can be isolated from the ethyl acetate extract of Lycopodium clavatum. -
Anti-inflammatory Agent
Anti-inflammatory agent 31 is a derivative of andrographolide that functions primarily by inhibiting NF-κB activation through the upstream blockade of the PI3K/Akt and ERK1/2 MAPK signaling pathways. This compound exhibits notable anti-inflammatory activity, promoting the recovery of intracellular glutathione (GSH) levels. Additionally, anti-inflammatory agent 31 demonstrates a protective effect on liver cells, making it a valuable tool for research applications in inflammation and hepatoprotection. -
Antioxidant/Anti-inflammatory/Anticancer Agent
Licoflavanone, a flavanone with antioxidant, anti-inflammatory, and anticancer properties, is isolated from the leaf extract of Glycyrrhiza glabra. It exerts its anticancer effects by downregulating the mTOR/PI3K/AKT signaling pathway, leading to inhibition of cancer cell proliferation, migration, and invasion. Additionally, Licoflavanone activates pro-apoptotic factors such as Bax and Bad, along with multiple caspase enzymes. Its anti-inflammatory activity involves reducing NF-κB nuclear translocation and decreasing the phosphorylation of p38, JNK, and ERK1/2, ultimately inhibiting pro-inflammatory cytokines, COX-2, and iNOS expression. This compound is utilized in research on nasopharyngeal carcinoma and its underlying mechanisms. -
CK1α Degrader
INNO-220 is a CRBN-dependent molecular glue degrader that specifically targets CK1α. This orally active compound induces cell cycle arrest at the G0/G1 phase and promotes apoptosis through the degradation of CK1α. Additionally, INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, effectively inhibiting NF-κB signaling in stimulated T cells and lymphoma cells with activating mutations in CARD11. This reagent serves as a valuable tool for advancing research in lymphoma. -
TMA /TMAO Inhinbitor
3,3-Dimethyl-1-butanol is an orally active inhibitor of trimethylamine (TMA) and trimethylamine N-oxide (TMAO), acting via the suppression of the p65 NF-κB signaling pathway and the TGF-β1/Smad3 pathway. This compound exhibits significant potential in the study of cardiovascular diseases (CVD), making it a valuable reagent for researchers investigating the molecular mechanisms underlying these conditions. -
GPR119 Agonist
2-Oleoylglycerol is a GPR119 agonist that activates hGPR119 in transiently transfected COS-7 cells with an EC50 value of 2.5 μM. This lipid enhances the inflammatory response in macrophages and promotes fibrosis through the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. Additionally, 2-Oleoylglycerol stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. Its effects make it a valuable tool for research into non-alcoholic steatohepatitis (NASH) and related metabolic disorders. -
Syk Inhibitor, NF-κB p65 Inhibitor, TGF-β1/Smad Signaling Inhibitor
Flavanomarein is a potent inhibitor of Syk and NF-κB p65, as well as a modulator of TGF-β1/Smad signaling pathways. This compound exhibits cytoprotective, anti-inflammatory, and antioxidant activities, enhancing AKT phosphorylation while regulating key proteins such as PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2, and ICAD. Flavanomarein also inhibits the nuclear translocation of NF-κB p65 and modulates epithelial-mesenchymal transition (EMT) markers, promoting proliferation in HK-2 cells and protecting neuronal cells from 6-OHDA-induced neurotoxicity. This compound is valuable for research on Parkinson's disease and diabetic nephropathy. -
Stable Isotope
2-Oleoylglycerol-d5 is a deuterium-labeled derivative of 2-Oleoylglycerol, a known agonist of GPR119. It exhibits significant biological activity by activating human GPR119 with an EC50 of 2.5 μM in COS-7 cells, enhancing macrophage inflammatory responses and promoting fibrosis through the GPR119/TAK1/NF-κB/TGF-β1 signaling cascade. Additionally, this compound stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol-d5 is particularly useful for studying mechanisms underlying non-alcoholic steatohepatitis (NASH). -
Essential Amino Acid
L-Cysteine hydrochloride hydrate is an essential amino acid that serves as a precursor for biologically active molecules, including hydrogen sulfide (H2S), glutathione, and taurine. It modulates the CBS/H2S pathway and has been shown to inhibit NF-κB activation, as well as regulate insulin and ghrelin secretion. This compound is involved in reducing blood glucose levels, vascular inflammation markers, and appetite, while also being noted for its potential to induce kidney damage. Its applications extend to research on neurological diseases and diabetes. -
HDAC Inhibitor
HDAC-IN-37 is a potent inhibitor of histone deacetylases (HDACs), demonstrating IC50 values of 0.0551 μM for HDAC1, 1.24 μM for HDAC3, 0.948 μM for HDAC8, and 34.2 μM for HDAC6. This compound effectively increases histone acetylation through a slow-off binding mechanism. Additionally, HDAC-IN-37 disrupts the transition from the G1 phase to the S phase of the cell cycle and promotes early apoptosis in various cell types, making it a valuable tool for research in cancer biology and therapeutic development. -
NF-κB Activator
Isochamaejasmin is a biflavonoid that acts as a potent activator of NF-κB. It exhibits significant anti-cancer properties by inducing apoptosis through the mitochondrial pathway and causing DNA damage in AW1 cells. In addition, Isochamaejasmin demonstrates moderate antiplasmodial activity against P. falciparum with an IC50 of 7.3 μM, while maintaining relatively low cytotoxicity (CC50 of 29.0 μM), making it valuable for various biological research applications. -
c-Met/HDAC Inhibitor
c-Met/HDAC-IN-3 is a dual inhibitor targeting c-Met and histone deacetylase 1 (HDAC1), exhibiting IC50 values of 12.50 nM and 26.97 nM, respectively. This compound demonstrates significant biological activity by inducing apoptosis and causing cell cycle arrest at the G2/M phase. c-Met/HDAC-IN-3 serves as a valuable tool for research in cancer biology and therapeutic development, particularly in studies focused on synergistic inhibition of oncogenic pathways. -
HDAC6 Inhibitor
HDAC6-IN-4 is a potent and selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 value of 23 nM. This compound promotes apoptosis in cancer cells and demonstrates significant antitumor efficacy while exhibiting minimal toxicity. HDAC6-IN-4 is valuable for research in cancer biology, particularly in studies focused on epigenetic regulation and therapeutic development.
